Summary
Researchers are looking for new ways to treat types of breast cancer that are both:
- High-risk, which means the cancer may have a higher chance of getting worse or
coming back after treatment
- Early-stage, which means the cancer is in the breast or the lymph nodes around the
breast The 2 types of breast cancer in this study are triple-negative breast cancer
(TNBC) and hormone receptor (HR)-low positive/human epidermal growth factor
receptor-2 (HER2) negative breast cancer. These cancers have zero or a low amount of
a protein called HER2 and other proteins that attach to the hormones estrogen or
progesterone.
Sacituzumab tirumotecan (also known as sac-TMT or MK-2870), the study medicine, is a type
of targeted therapy. A targeted therapy is a treatment that works to control how specific
types of cancer cells grow and spread.
The main goals of this study are to learn if people who receive sac-TMT, pembrolizumab,
and chemotherapy:
- Have fewer cancer cells found in the tumors and lymph nodes removed during surgery
compared to those who receive only pembrolizumab and chemotherapy
- Live longer without the cancer growing, spreading, or coming back compared to people
who receive only pembrolizumab with chemotherapy